The Bristol-Myers Squibb Children’s Hospital Receives $2.5 Million Gift from Bristol Myers Squibb Foundation to Mark 20th Anniversary

Dedicated Pediatric Infusion Center Planned to Address Increase in Outpatient Biologic Therapies

BMSCH child patient back to playing tennis
Ten-year-old Elli was treated at BMSCH in 2018 after a biking accident led to a blood clot requiring emergency brain surgery
(New Brunswick, NJ) The Bristol-Myers Squibb Children’s Hospital (BMSCH) at Robert Wood Johnson University Hospital (RWJUH), a RWJBarnabas Health facility, has received a $2.5 million commitment from The Bristol Myers Squibb Foundation in honor of the hospital’s 20th anniversary of caring for the children of New Jersey.

The gift will support a dedicated pediatric infusion center to provide a child-appropriate site for outpatient biologic drug treatments at BMSCH. Such treatments are becoming standard of care in gastroenterology, rheumatology, genetics, neurology and nephrology and others.

“The Bristol Myers Squibb foundation’s unwavering support of our children’s health mission over the past twenty years is truly remarkable,” said Bill Arnold, President and CEO, Robert Wood Johnson University Hospital. “They continue to be our steadfast partner at BMSCH, and will again help transform our ability to deliver the latest, essential therapies to children in New Jersey and the region.”

“The need for a pediatric infusion center will only expand over the coming years, and this generous gift will place us at the forefront in treatment modalities,” said William Faverzani, vice president and Chief Administrative Officer, Bristol-Myers Squibb Children’s Hospital at Robert Wood Johnson University Hospital. “We are so grateful that the Bristol Myers Squibb Foundation continues to support our mission to improve children’s health as we enter our third decade, as they have for the past 20 years.”

The addition of a pediatric infusion center will provide family-centered care to children requiring short or long-term infusion therapy, therapeutic injections, sedation or provocative stimulation testing. Infusion therapy will be administered to infants, children, and adolescents who require either one-time or ongoing IV therapy for a variety of acute and chronic illnesses including gastrointestinal, rheumatologic, immune, genetic, neurologic, renal, endocrine, and blood disorders. With a dedicated center in close proximity to the Pediatric Intensive Care Unit, patients receiving infusions will have highly skilled and personalized care with the convenience of an outpatient setting.

John Damonti, President of the Bristol Myers Squibb Foundation commented, “We are proud to support the pediatric infusion center as part of our long-term commitment to The Bristol-Myers Squibb Children’s Hospital at the Robert Wood Johnson University Hospital. In line with our priority to facilitate access to high quality care for every patient, we recognize the need for a child-appropriate facility and are delighted to help the hospital realize its vision.”

“The RWJ University Hospital Foundation’s twenty-year partnership with the Bristol Myers Squibb Foundation has allowed our facility to provide life-changing services to pediatric patients throughout the region,” said Mary Burke, vice president, RWJ University Hospital Foundation. “We look forward to continuing to work together on improving the experience and providing spaces for our pediatric patients to heal.”

To learn more about the comprehensive care we provide, visit The Bristol-Myers Squibb Children’s Hospital at RWJUH.